METHYLIN ER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for METHYLIN ER (METHYLIN ER).

How it works

Methylphenidate is a central nervous system stimulant that blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their availability in the synaptic cleft.

What the body does with it

Metabolism	Primarily de-esterified by carboxylesterase 1 (CES1) to the inactive metabolite ritalinic acid. Minor hepatic metabolism via CYP2D6.
Excretion	Renal (90% as metabolites, <1% unchanged). Biliary/fecal: <2%.
Half-life	Mean 3-6 hours in adults; longer in children (4-8 hours). Clinical context: steady-state reached within 2 days; dosing every 8-12 hours.
Protein binding	Methylphenidate: 10-33%, primarily to albumin. Metabolite ritalinic acid: ~50% bound.
Volume of Distribution	2.6-4.0 L/kg. Indicates extensive tissue distribution.
Bioavailability	Oral: 11-52% (low and variable due to first-pass metabolism).
Onset of Action	Oral ER: 0.5-1 hour (immediate release component); peak effect 2-4 hours.
Duration of Action	Oral ER: 8-12 hours. Note: duration may be shorter in children; individual variation requires titration.

Classification & Brands

Dosing & administration

20-60 mg orally once daily in the morning

Dosage form	TABLET, EXTENDED RELEASE
Renal impairment	No adjustment needed for GFR >30 mL/min; insufficient data for GFR <30 mL/min
Liver impairment	Child-Pugh Class A: no adjustment; Class B or C: reduce dose by 50%
Pediatric use	6 years and older: 18-54 mg orally once daily; weight-based: 0.3-1 mg/kg/dose, max 54 mg/day; not recommended under 6 years
Geriatric use	Start at low end of dosing range (20 mg daily) due to potential increased sensitivity; monitor cardiovascular status

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for METHYLIN ER (METHYLIN ER).

Breastfeeding	Methylphenidate is excreted into human breast milk with an M/P ratio of approximately 2-3 (range 1.1-4.4). Infant exposure is estimated at 0.2-0.7% of maternal weight-adjusted dose. Use with caution; monitor infant for agitation, insomnia, and reduced weight gain.
Teratogenic Risk	Methylphenidate is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of fetal anomalies (cardiac, skeletal) at high doses. Second trimester: Potential for decreased fetal growth with chronic use. Third trimester: Risk of neonatal withdrawal syndrome (tachycardia, irritability, poor feeding) and premature delivery.

Warnings & precautions

■ FDA Black Box Warning

Abuse and dependence: CNS stimulants, including methylphenidate, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to methylphenidate or any component of the formulation","Concurrent treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing an MAOI","Glaucoma","Tics or family history of Tourette's syndrome","Severe hypertension or symptomatic cardiovascular disease","Hyperthyroidism"]

Clinical Precautions

Precautions

["Risk of abuse and dependence","Serious cardiovascular events: sudden death, stroke, myocardial infarction in patients with pre-existing structural cardiac abnormalities or other serious heart problems","Blood pressure and heart rate increase","Psychiatric adverse events: exacerbation of pre-existing psychosis, mania, aggression, new psychotic or manic symptoms","Seizures: may lower seizure threshold","Priapism","Peripheral vasculopathy including Raynaud's phenomenon","Long-term suppression of growth in pediatric patients"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

METHYLIN ER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for METHYLIN ER (METHYLIN ER).

How it works

Methylphenidate is a central nervous system stimulant that blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their availability in the synaptic cleft.

What the body does with it

Metabolism	Primarily de-esterified by carboxylesterase 1 (CES1) to the inactive metabolite ritalinic acid. Minor hepatic metabolism via CYP2D6.
Excretion	Renal (90% as metabolites, <1% unchanged). Biliary/fecal: <2%.
Half-life	Mean 3-6 hours in adults; longer in children (4-8 hours). Clinical context: steady-state reached within 2 days; dosing every 8-12 hours.
Protein binding	Methylphenidate: 10-33%, primarily to albumin. Metabolite ritalinic acid: ~50% bound.
Volume of Distribution	2.6-4.0 L/kg. Indicates extensive tissue distribution.
Bioavailability	Oral: 11-52% (low and variable due to first-pass metabolism).
Onset of Action	Oral ER: 0.5-1 hour (immediate release component); peak effect 2-4 hours.
Duration of Action	Oral ER: 8-12 hours. Note: duration may be shorter in children; individual variation requires titration.

Classification & Brands

Dosing & administration

20-60 mg orally once daily in the morning

Dosage form	TABLET, EXTENDED RELEASE
Renal impairment	No adjustment needed for GFR >30 mL/min; insufficient data for GFR <30 mL/min
Liver impairment	Child-Pugh Class A: no adjustment; Class B or C: reduce dose by 50%
Pediatric use	6 years and older: 18-54 mg orally once daily; weight-based: 0.3-1 mg/kg/dose, max 54 mg/day; not recommended under 6 years
Geriatric use	Start at low end of dosing range (20 mg daily) due to potential increased sensitivity; monitor cardiovascular status

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for METHYLIN ER (METHYLIN ER).

Breastfeeding	Methylphenidate is excreted into human breast milk with an M/P ratio of approximately 2-3 (range 1.1-4.4). Infant exposure is estimated at 0.2-0.7% of maternal weight-adjusted dose. Use with caution; monitor infant for agitation, insomnia, and reduced weight gain.
Teratogenic Risk	Methylphenidate is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of fetal anomalies (cardiac, skeletal) at high doses. Second trimester: Potential for decreased fetal growth with chronic use. Third trimester: Risk of neonatal withdrawal syndrome (tachycardia, irritability, poor feeding) and premature delivery.